Dinh, A., Sriprasert, I., Williams, A
Heres a summarised comparison: Key take-aways: Use PBS when in doubt especially for sensitive peptides like ARA-290
Incretin-based drugs are now being investigated and in some cases approved for a wide range of conditions, including cardiovascular disease, chronic kidney disease, sleep apnea, fatty liver disease (MASLD), neurodegenerative disorders, and even substance-use disorders
In spite of numerous reports implicating TMAO with CRC, there is a lack of empirical mechanistic evidences to concretize the involvement of TMAO in the carcinogenesis of CRC
Blood sugar regulation and metabolic support
In the UK, NICE recommends GLP-1 receptor agonists for type 2 diabetes in specific circumstances (NG28), such as when metformin is insufficient and BMI 30 kg/m